Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
FOCUS 1 and 2 trials: Two Phase III, randomised, double-blind, multinational, multicentre, non-inferiority trials comparing Zinforo (600 mg IV every 12 hours, adjusted for moderate renal impairment) vs ceftriaxone (1 g IV every 24 hours)2
Clinical cure rates: FOCUS 1 and 2||
||The lower limit of the 95% CI was above –10%, which met the predefined criteria for non-inferiority.7 Zinforo was well tolerated with a safety profile similar to that of ceftriaxone.7
‡Zinforo may be associated with early clinical response, based on clinical stability and symptom improvement criteria. Early clinical response does not predict final clinical outcome for Zinforo.
*CrCL 31–50 mL/min.2
† Shown not to be statistically significant.3
§ Bacteraemia was present in 4% of patients when baseline medical characteristics were assessed.2
**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1
Prescribing Information
Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion
Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials
** This is an optional area where footnotes can live.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
No
OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?